Basic Neurosciences · Paper A
Apoe4 and Alzheimer's disease
APOE4 loads the dice for the common, late-onset form of Alzheimer's disease — it never rolls them for you. Each ε4 copy (allele — one version of the APOE gene, of which everyone carries two) shaves a little more efficiency off the brain's amyloid-clearing machinery, raising risk and pulling the average age of onset earlier, while the rarer ε2 copy does the reverse. That is a completely different story from the handful of genes — APP, PSEN1, PSEN2 — whose mutations are a switch that always flips the light on, or from Down syndrome's extra whole copy of the amyloid gene itself. What actually separates these findings is whether the vignette describes a probability shift or a certainty.
Picture a memory clinic where two very different people are being asked about their family history. One is 76 and has been forgetting appointments for two years; a blood test looks at a common gene variant, APOE4 (the ε4 form of the APOE gene), that nudges her risk of memory problems up or down, the same way it does for everyone else in the room, just by a different amount. The other is 38, and three generations of his family developed an identical, unstoppable dementia in their thirties and forties; his genetic test is not measuring a nudge at all — it is confirming a fault that, once inherited, was always going to cause the disease. Same test category, "Alzheimer's disease genetics," two completely different kinds of answer. This page is about telling those kinds apart.
APOE (apolipoprotein E, a protein that ferries cholesterol and other fats around the body, including inside the brain, and helps clear waste products from between brain cells) is a gene everyone carries two copies of, one from each parent. Each copy is one of three common versions — ε2, ε3 or ε4 (the Greek letter epsilon is simply how geneticists label these three versions). ε3 is the most common and is treated as the "neutral" baseline. Carrying an ε4 copy raises the chance of developing the common, late-onset form of Alzheimer's disease later in life; carrying an ε2 copy lowers it. "APOE4" usually refers to the ε4 version specifically, and it is by far the most important common genetic risk factor doctors discuss for ordinary, late-life Alzheimer's disease.
Here is the trap almost every exam candidate falls into: hearing "the Alzheimer's gene" and assuming carrying it means you will get the disease, or that everyone with the disease must carry it. Neither is true. APOE4 is neither necessary nor sufficient — necessary would mean you cannot get the disease without it, sufficient would mean having it guarantees you will — it only shifts the odds. Plenty of people carry two copies of ε4 and live into old age with no dementia at all, and plenty of people develop Alzheimer's disease with no ε4 copy whatsoever. If a vignette describes a gene fault that is guaranteed to cause disease in every carrier, it is describing something else entirely — one of the rare, fully penetrant mutations covered further down this page, not APOE4.
Start from what apolipoprotein E actually does: it helps escort amyloid-beta (a sticky protein fragment that, when it builds up between neurons, is a hallmark of Alzheimer's disease) out of the brain. The three APOE versions do this job with different efficiency. The ε2 version clears amyloid-beta most efficiently, ε3 does an average job, and ε4 does it least efficiently of the three. Less efficient means amyloid-beta accumulates faster over a lifetime, which is why ε4 raises risk and brings the average age of first symptoms earlier, while ε2 does the opposite.
Because everyone carries two copies, the effect is a dose. Take a heterozygote (someone carrying two different versions of a gene) with one ε4 copy and one ε3 copy, and compare them with a homozygote (someone carrying two identical copies of a gene) who has two ε4 copies: the homozygote's amyloid-clearing machinery is doing the less efficient job on both copies instead of just one, so their risk is higher again than the heterozygote's. That dose relationship — more copies, more risk, earlier onset — is the single fact this whole topic turns on.
Contrast APOE4 with three rare genes — APP, PSEN1 and PSEN2 — whose mutations behave completely differently. A mutation in any of these three causes early-onset familial Alzheimer's disease: inheritance is autosomal dominant (one faulty copy from one parent is enough to pass it on), and for APP and PSEN1 especially, penetrance (the proportion of carriers who go on to develop the disease) is essentially complete. PSEN1 mutations are the most common cause of this familial form and typically produce symptoms in a carrier's thirties to fifties — decades earlier than the late-onset disease APOE4 influences. PSEN2 behaves similarly but is rarer and less completely penetrant.
Then there is trisomy 21, or Down syndrome (having three copies of chromosome 21 instead of the usual two). One of the genes on chromosome 21 is the APP gene itself, so an extra whole chromosome means an extra whole copy of that gene, and a lifetime of extra amyloid production as a result. That single dosage effect is powerful enough that the great majority of people with Down syndrome develop Alzheimer's neuropathology by their forties — not because of an APOE result at all, but because of an entire extra chromosome.
| Looks like APOE4 | How to tell it apart |
|---|---|
| APOE2 | Same gene, opposite direction of effect: lowers risk and delays onset instead of raising it |
| PSEN1 / PSEN2 mutation | Rare, autosomal dominant, (near-)fully penetrant — causes early-onset familial disease, not a late-life risk nudge |
| APP gene mutation | Same deterministic, early-onset pattern as PSEN1/PSEN2, from a mutation in the amyloid precursor protein gene itself |
| Trisomy 21 (Down syndrome) | An extra whole chromosome carrying an extra APP gene copy, not a single-gene variant |
| MAPT, C9orf72, GRN, PRNP mutations | Cause genetically distinct dementias (frontotemporal dementia, prion disease) with their own clinical patterns, not Alzheimer's disease |
APOE genotyping is not a diagnostic test for Alzheimer's disease and is not routinely used to diagnose it — a diagnosis still rests on the clinical history, cognitive assessment and, where indicated, structural or functional imaging to exclude other causes. Where APOE testing is used, it is mainly in research settings or specialist genetic counselling, precisely because a risk-raising result cannot confirm or exclude disease in an individual. This is different from the rare familial genes: a positive PSEN1, PSEN2 or APP mutation result in someone with a strong family history is much closer to a definitive answer, because penetrance is so high.
There is no APOE4-specific drug and no treatment decision in routine NHS care that turns on someone's APOE genotype alone. NICE NG97 (Dementia: assessment, management and support) sets out how a diagnosis of dementia, including Alzheimer's disease, is actually managed once made: cognitive stimulation and structured support for the person and their carers, cholinesterase inhibitors (for example donepezil) for mild-to-moderate Alzheimer's disease, and active management of modifiable vascular risk factors such as hypertension and diabetes, which can accelerate cognitive decline in someone who also carries Alzheimer's pathology. For the rare familial mutations, genetic counselling for at-risk relatives is the real management step that follows a positive result, because of how much more certain the future risk is.
Whenever a vignette hands you an "Alzheimer's disease genetics" question, do not stop at recognising the gene name — ask whether the picture described is a dose-dependent nudge in population-wide risk, or a family history where the mutation guarantees the disease in every carrier. That single question is what actually separates APOE4 from PSEN1, PSEN2 and APP mutations, and it is very rarely spelled out for you in so many words. Before moving on, try explaining to a friend why someone can carry two copies of a "risk gene" for Alzheimer's disease and never develop it.
APOE4 nudges the odds of late-onset Alzheimer's disease up (and APOE2 nudges them down) in a dose-dependent way, which is fundamentally different from the rare, fully penetrant mutations and the whole-chromosome dosage effect that actually guarantee early-onset disease in their carriers.